It ended up being cancer, not heart complications that led to the Belviq recall in February 2020. A clinical trial conducted between 2014 and 2018—during the period when the drug was approved and being prescribed by doctors—found an increased risk of cancer in Belviq users. More than other cancers, people who took Belviq were diagnosed with pancreatic, colorectal, and lung cancer.